Quest Diagnostics Incorporated (DGX) : 15 analysts are covering Quest Diagnostics Incorporated (DGX) and their average rating on the stock is 3.02, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. 1 more analyst has given the stock a Sell recommendation. A total of 12 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Quest Diagnostics Incorporated (DGX) : The consensus price target for Quest Diagnostics Incorporated (DGX) is $79.55 for the short term with a standard deviation of $6.2. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $90, however, the pessimist price target for the company is $70.
Company shares have received an average consensus rating of Hold for the current week Quest Diagnostics Incorporated (NYSE:DGX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $85.63 and $85.35 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $86.19. The buying momentum continued till the end and the stock did not give up its gains. It closed at $86.06, notching a gain of 0.82% for the day. The total traded volume was 797,986 . The stock had closed at $85.36 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Leiden Jeffrey M, director of Quest Diagnostics Inc, had unloaded 6,345 shares at an average price of $85.63 in a transaction dated on August 3, 2016. The total value of the transaction was worth $543,322.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.